Brief: Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial
15/05/2026 12:09
Racura Oncology Ltd RAC.AX: RACURA ONCOLOGY ANNOUNCES POSITIVE SAFETY REVIEW COMMITTEE RECOMMENDATION IN ONGOING CPACS CLINICAL TRIAL RACURA ONCOLOGY LTD - NO SAFETY CONCERNS NOTED WITH RC220 ALONE OR WITH DOXORUBICIN IN FIRST COHORT RACURA ONCOLOGY LTD - TO INITIATE SCREENING FOR COHORT 2 AT 80MG/M2 RC220 DOSE LEVEL Source text: ID:nPnFTMRka Further company coverage: RAC.AX
Recent news on Racura Oncology
See all newsAustralia's Racura Oncology jumps most in a month after raising $24 million
Brief: Racura Oncology Says Emerging Companies Specialist Invests In Racura
Brief: Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial
Australia's Racura Oncology gains on Purdue University cancer study collab
Brief: Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220